Lupin posts Q1 FY2016 results
Records Rs 8,922 million EBITDA during Q1 FY2016 Lupin has posted its performance for the first quarter ending June 30, 2015.…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Lupin
Lupin expects ANVISA clearance for beta-lactam cephalosporin APIs by September
ANVISA's suspension order dated May 13 states the reason of its action as "analysis considered unsatisfactory
Reacting to news…
Lupin acquires Biocom in Russia
Biocom is a generic pharma company with a major focus on therapies such as cardiovascular, central nervous system and…
Lupin posts Q4 FY 2014-15 results
Acquires Brazil-based Medquímica Indústria Farmacêutica Lupin has posted its performance for the fourth quarter and the…
Lupin in agreement with Salix Pharmaceuticals, launches Zaxine in Canada
The agreement grants Lupin exclusive rights to promote, distribute and market Zaxine in Canada
Lupin launches generic exforge tabs in US
Lupin’s Amlodipine and Valsartan tablets are indicated for the treatment of hypertension and to lower blood pressure
Lupin, Rotary announce joint campaign
The primary aim would be to enhance awareness and ensure timely diagnosis and treatment Lupin along with the Rotary Club, Mumbai,…
Lupin bags US FDA approval
Generic lumigan ophthalmic solution is indicated for the reduction of elevated intraocular pressure in patients
Lupin and Celon in agreement
Celon will supply the product to Lupin for its commercialisation in the US, Canada, Mexico, and other key markets
Lupin receives FDA nod for generic vancocin capsules
Vancocin capsules had annual US sales of $ 164.2 million.